# Developmental Funds

> **NIH NIH P30** · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · 2024 · $274,813

## Abstract

DEVELOPMENTAL FUNDS
PROJECT SUMMARY/ABSTRACT
Rutgers Cancer Institute of New Jersey (CINJ) leverages funding from the CCSG and
Institutional/Philanthropic support to: 1) offer an array of pilot project opportunities spanning basic, clinical,
translational, and population science research topics important to achieving the goals of our Strategic Plan
and in alignment with catchment area priorities; and 2) provide New Investigator Awards (NIAs) to cancer-
focused research faculty new to Rutgers (RU) and Princeton (PU) Universities and cancer-related research
faculty established at Rutgers and Princeton Universities. The ultimate goals are to increase cancer focus,
integrate the five Research Programs, and increase collaboration with Center Members (these awards are
not synonymous and are in addition to faculty recruitment start-up funds).
In an effort to accelerate our progress toward meeting Strategic Plan goals, CINJ leveraged its status as the
only NCI-designated Comprehensive Cancer Center in New Jersey to garner additional institutional
commitment, supplemented by generous philanthropic and State support, to establish four new Centers of
Excellence (Pediatric Cancer and Blood Disorder Research, Immunology/Metabolism, Cancer Survivorship,
and Outcomes, and Cancer Health Equity) with annual budgets containing funding for pilot awards.
Establishment of the Princeton Branch of the Ludwig Institute for Cancer Research created additional
opportunities to engage PU members in immunology and metabolism research.
CINJ’s process for Developmental Funds administration has been enhanced (more frequent and detailed
reporting) and made more efficient over this grant period by utilizing two new decision support tools: the
InfoReady platform, a shared investment with Rutgers University, for automated award review and reporting,
and EVAL as the data warehouse for Developmental Funds awards and demonstrable outcomes.
CINJ’s oversight of Developmental Funds resulted in strong ROI from its Pilot Project and New Investigator
Awards in the form of publications, extramural funding (peer-reviewed and non-peer-reviewed), clinical trials,
training activities, community outreach activities, bidirectional communication with the community, policy-
related activities, and commercialization activities. In this grant period, 28 pilot projects were awarded and
completed (resulting in nine peer-reviewed, extramural awards), and an additional 19 pilot projects received
funding in the last 12 months. Philanthropic funds were leveraged for a pilot award to Eileen White allowing
for the generation of preliminary data resulting in a successful CRUK/NCI Grand Challenge application.
Twelve New Investigator Awards over this grant period resulted in eight peer-reviewed, extramural awards.
In addition, after research leadership endorsed Dr. Zhiyuan Shen to develop a P01 application, Libutti worked
with the Rutgers University Foundation to secure $2M in seed funding which enabled the gene...

## Key facts

- **NIH application ID:** 10767727
- **Project number:** 2P30CA072720-25
- **Recipient organization:** RUTGERS BIOMEDICAL AND HEALTH SCIENCES
- **Principal Investigator:** STEVEN K. LIBUTTI
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $274,813
- **Award type:** 2
- **Project period:** 1997-03-01 → 2029-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10767727

## Citation

> US National Institutes of Health, RePORTER application 10767727, Developmental Funds (2P30CA072720-25). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10767727. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*